FDA advisers back Pfizer's COVID treatment for full approval

Published 03/16/2023, 09:36 AM
Updated 03/16/2023, 04:06 PM
© Reuters. FILE PHOTO: The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/

By Leroy Leo and Khushi Mandowara

(Reuters) -Advisers to the U.S. Food and Drug Administration on Thursday overwhelmingly backed full approval of Pfizer (NYSE:PFE)'s oral antiviral COVID-19 treatment Paxlovid for adults at high risk of progression to severe disease.

The FDA's panel of outside experts voted 16-to-1 in favor of the drug's benefits outweighing its risk for some adults with mild-to-moderate COVID-19.

The agency is expected to make a formal approval decision by May and typically follows the advice of its expert advisers, but is not required to do so.

A full approval will eventually allow Pfizer to sell Paxlovid - which consists of two drugs in pill form - at market rates on the private market in the U.S., rather than through government contracts as it has been thus far.

Pfizer has sold the U.S. government nearly 24 million courses of Paxlovid at around $530 a course. As of March 12, the U.S. had distributed about 12.7 million courses and more than 8.5 million have been dispensed, according to government data. 

A full approval also would provide doctors more flexibility in prescribing the drug and also allow the company to expand its advertising campaign.

Thursday's positive vote came after the FDA and Pfizer provided data assuaging concerns about the potential for a rebound in COVID symptoms after a five-day course of treatment.

Numerous anecdotal reports of a return of symptoms following Paxlovid treatment, including in high profile patients such as President Joe Biden and Dr. Anthony Fauci, had raised concerns.

Several panel members said they were reassured by the data presented on the COVID rebound issue.

© Reuters. FILE PHOTO: The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/

Paxlovid has been authorized for emergency use in the U.S. in mild-to-moderate COVID patients aged 12 years and older since late 2021, but Pfizer's application for full approval only covers high-risk adults.

The FDA earlier on Thursday said the current Paxlovid emergency use authorization (EUA) for high-risk adolescents will continue to remain in effect even if it receives full approval for use in older patients.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.